Tags

Type your tag names separated by a space and hit enter

Prevalence of Apolipoprotein E Polymorphisms in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: A Northern Greece Study.
Neurodegener Dis. 2018; 18(4):216-224.ND

Abstract

BACKGROUND

Apolipoprotein E ε4 allele (APOEε4) is a major genetic risk factor for Alzheimer's disease (AD). APOEε4 carriers have a higher risk of cognitive impairment and AD in a gene dose-dependent manner. The above notion is investigated in the Greek population.

METHODS

A sample of 1,703 subjects (967 AD patients, 576 mild cognitive impairment [MCI] and 160 Healthy Elderly), was genotyped for APOE from 2008 to 2017. DNA was extracted from peripheral blood using the QIAamp Blood DNA purification kit (Qiagen Inc., USA). Descriptive statistics, one-way analysis of variance with Bonferroni post hoc tests, Pearson chi-square test, and binary logistic regression models were used for the statistical analysis.

RESULTS

The APOE genotype and allele frequencies in AD group were significantly different from those in the Control and MCI groups. The frequencies of ε4/4 homozygotes were 1.9, 1.6, and 5.7%, while the ε4/- carriers' distribution was 22.5, 24.1, and 37.4% in the Control, MCI, and AD groups respectively. The estimated odds of ε4/4 for AD was 5.731-fold higher compared to the estimated odds of ε3/3. The interaction between gender and APOE did not have a significant effect on the odds for MCI (p = 0.942) and AD (p = 0.984).

CONCLUSION

In Greece, APOE ε4 presence is related to an increased risk for AD in a dose-related manner. Contrary to long-standing views, men and women with the APOE ε4 genotype have nearly the same odds of developing MCI and AD.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Tsolaki AC
Neurology Clinic, 1st General Hospital of Thessaloniki "Agios Pavlos", Thessaloniki, Greece. Greek Association of Alzheimer's Disease and Related Disorders, Thessaloniki, Greece. Medical Physics Laboratory, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Gatzima O
Greek Association of Alzheimer's Disease and Related Disorders, Thessaloniki, Greece.
Daniilidou M
Department of Neurosciences, Akademiska Hospital, Uppsala University, Uppsala, Sweden.
Lazarou E
First Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece. Greek Association of Alzheimer's Disease and Related Disorders, Thessaloniki, Greece.
Bamidis PD
Medical Physics Laboratory, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Verykouki E
Department of Hygiene, Social-Preventive Medicine and Medical Statistics, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Iakovidou-Kritsi Z
Laboratory of Medical Biology-Genetics Department of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Tsolaki M
First Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece. Greek Association of Alzheimer's Disease and Related Disorders, Thessaloniki, Greece.

MeSH

AgedAged, 80 and overAlzheimer DiseaseApolipoproteins ECognition DisordersCognitive DysfunctionFemaleGene FrequencyGenotypeGreeceHumansMaleMiddle AgedPolymorphism, GeneticPrevalenceRisk

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30205398

Citation

Tsolaki, Anthoula C., et al. "Prevalence of Apolipoprotein E Polymorphisms in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: a Northern Greece Study." Neuro-degenerative Diseases, vol. 18, no. 4, 2018, pp. 216-224.
Tsolaki AC, Gatzima O, Daniilidou M, et al. Prevalence of Apolipoprotein E Polymorphisms in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: A Northern Greece Study. Neurodegener Dis. 2018;18(4):216-224.
Tsolaki, A. C., Gatzima, O., Daniilidou, M., Lazarou, E., Bamidis, P. D., Verykouki, E., Iakovidou-Kritsi, Z., & Tsolaki, M. (2018). Prevalence of Apolipoprotein E Polymorphisms in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: A Northern Greece Study. Neuro-degenerative Diseases, 18(4), 216-224. https://doi.org/10.1159/000491764
Tsolaki AC, et al. Prevalence of Apolipoprotein E Polymorphisms in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: a Northern Greece Study. Neurodegener Dis. 2018;18(4):216-224. PubMed PMID: 30205398.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence of Apolipoprotein E Polymorphisms in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: A Northern Greece Study. AU - Tsolaki,Anthoula C, AU - Gatzima,Olympia, AU - Daniilidou,Makrina, AU - Lazarou,Eutuxia, AU - Bamidis,Panagiotis D, AU - Verykouki,Eleni, AU - Iakovidou-Kritsi,Zafiroura, AU - Tsolaki,Magda, Y1 - 2018/09/11/ PY - 2018/01/22/received PY - 2018/07/02/accepted PY - 2018/9/12/pubmed PY - 2019/1/5/medline PY - 2018/9/12/entrez KW - Alzheimer’s disease KW - Apolipoprotein E KW - Greek population KW - Mild cognitive impairment SP - 216 EP - 224 JF - Neuro-degenerative diseases JO - Neurodegener Dis VL - 18 IS - 4 N2 - BACKGROUND: Apolipoprotein E ε4 allele (APOEε4) is a major genetic risk factor for Alzheimer's disease (AD). APOEε4 carriers have a higher risk of cognitive impairment and AD in a gene dose-dependent manner. The above notion is investigated in the Greek population. METHODS: A sample of 1,703 subjects (967 AD patients, 576 mild cognitive impairment [MCI] and 160 Healthy Elderly), was genotyped for APOE from 2008 to 2017. DNA was extracted from peripheral blood using the QIAamp Blood DNA purification kit (Qiagen Inc., USA). Descriptive statistics, one-way analysis of variance with Bonferroni post hoc tests, Pearson chi-square test, and binary logistic regression models were used for the statistical analysis. RESULTS: The APOE genotype and allele frequencies in AD group were significantly different from those in the Control and MCI groups. The frequencies of ε4/4 homozygotes were 1.9, 1.6, and 5.7%, while the ε4/- carriers' distribution was 22.5, 24.1, and 37.4% in the Control, MCI, and AD groups respectively. The estimated odds of ε4/4 for AD was 5.731-fold higher compared to the estimated odds of ε3/3. The interaction between gender and APOE did not have a significant effect on the odds for MCI (p = 0.942) and AD (p = 0.984). CONCLUSION: In Greece, APOE ε4 presence is related to an increased risk for AD in a dose-related manner. Contrary to long-standing views, men and women with the APOE ε4 genotype have nearly the same odds of developing MCI and AD. SN - 1660-2862 UR - https://www.unboundmedicine.com/medline/citation/30205398/Prevalence_of_Apolipoprotein_E_Polymorphisms_in_Alzheimer's_Disease_Mild_Cognitive_Impairment_and_Healthy_Elderly:_A_Northern_Greece_Study_ DB - PRIME DP - Unbound Medicine ER -